Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms

Cancer Gene Therapy

Volumn 7, Issue 1, 2000, Pages 118-127

  Kruse, Carol A ^a   Lamb, Carilee ^a   Hogan, Suzanne ^a   Smiley, W Russell ^b   Kleinschmidt DeMasters, Bette K ^a   Burrows, Francis J ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Astrocytoma; Brain tumor; Glioblastoma; Retroviral vectors; Suicide gene therapy

Indexed keywords

CANCER ANTIBODY; DEXAMETHASONE; GANCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CONTACT; CONTROLLED STUDY; GENE THERAPY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; MALE; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUICIDE GENE; TREATMENT OUTCOME; TUMOR VOLUME; VIRUS PARTICLE;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0033980574     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700097     Document Type: Article

References (35)

1. Laws ER Jr, Thapar K. Brain tumors. Cancer. 1993;43: 263-271.
2. Kruse CA, Merchant RE. Cellular therapy of brain tumors: clinical trials. In: Kornblith PL, Walker MD, eds. Advances in Neuro-Oncology II. Armonk, NY: Futura Publishing Co., Inc.; 1997:487-504.
3. Ram Z, Oldfield EH. Genetic approaches for the therapy of malignant brain tumors. In: Kornblith PL, Walker MD, eds. Advances in Neuro-Oncology II. Armonk, NY: Futura Publishing Co., Inc.; 1997:541-551.
4. Couldwell WT, Mitchell MS, Mazumder AM, Apuzzo MLJ. Immunology and immunotherapy of intrinsic glial tumors. In: Apuzzo MLJ, ed. Malignant Cerebral Glioma. Park Ridge, Ill: AANS Publication; 1990:41-57.
5. Kruse CA, Roper MD, Kleinschmidt-DeMasters BK, et al. Purified herpes simplex thymidine kinase retrovector particles. I. In vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors. Cancer Gene Ther. 1997;4:118-128.
6. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, et al. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neurooncol. 1993;15:97-112.
7. Brown BW Jr, Hollander M. In Statistics. A Biomedical Introduction. New York: Wiley and Sons; 1977:343-346.
8. Crowle AJ. Precipitation and microprecipitation reactions in fluid medium and in gels. In: Rose NR, Friedman H, eds. Manual of Clinical Immunology. Washington, DC: American Society of Microbiology Publication; 1980:2-14.
9. Emmett M, Crowle AJ. Crossed immunoelectrophoresis technique. Clin Immunol Newsl. 1981;99:99-103.
10. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
11. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors. Cancer Res. 1993;53:83-88.
12. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
13. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996;3:85-92.
14. Wu JK, Cano WG, Meylaerts SAG, Qi P, Vrionis F, Cherington V. Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery. 1994;35: 1094-1103.
15. Dilber MS, Abedi MR, Christensson B, et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 1997;57:1523-1528.
16. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
17. Shinoura N, Chen L, Wani MA, et al. Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy. J Neurosurg. 1996;84:839-846.
18. Tamura M, Shimizu K, Yamada M, Miyao Y, Hayakawa T, Ikenaka K. Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells. Hum Gene Ther. 1997;8:381-391.
19. Ram Z, Culver KW, Oshior EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 1997;3:1354-1361.
20. Vrionis FD, Wu JK, Qi P, Cano WG, Cherington V. Preservation of the bystander cytocidal effect of irradiated herpes simplex virus thymidine kinase (HSV-tk) modified tumor cells. J Neurooncol. 1996;30:225-236.
21. Iwadate Y, Namba H, Tagawa M, Takenaga K, Sueyoshi K, Sakayama S. Induction of acquired immunity in rats that have eliminated intracranial gliosarcoma cells by the expression of herpes simplex virus-thymidine kinase gene and ganciclovir administration. Oncology. 1997;54:329-334.
22. Cool V, Pirotte B, Gerard C, et al. Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. Hum Gene Ther. 1996;7:627-635.
23. Rainov NG, Kramm CM, Aboody-Guterman K, et al. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther. 1996;3:99-106.
24. Barba D, Hardin J, Sadelain M, Gage F. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
25. Hahn JF. Cerebral edema and neurointensive care. Pediatr Clin North Am. 1980;27:587-592.
26. Watling CJ, Lee DH, Macdonald DR, et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol. 1994;12:1886-1889.
27. Paliogianni F, Boumpas DT. Glucocorticoids regulate calcineurin-dependent trans-activating pathways for interleukin-2 gene transcription in human T lymphocytes. Transplantation. 1995;59:1333-1339.
28. Ram Z, Culver KW, Walbridge S, Frank JA, Blaese M, Oldfield EH. Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg. 1993;79:400-407.
29. Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg. 1994;80:256-260.
30. Gagandeep S, Brew R, Green B, et al. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect." Cancer Gene Ther. 1996;3: 83-88.
31. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue-specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994;54:6228-6234.
32. Freeman S, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet. 1997;349:2-3.
33. Barth RF. Rat brain tumor models in experimental neurooncology: the 9L, C6, T9, F98, RG2 (D74), RT-2, and CNS-1 gliomas. J Neurooncol. 1998;36:91-102.
34. Blume MR, Wilson CB, Vasquez DA. Immune response to a transplantable intracerebral glioma in rats. In: Sane K, Ishi S, LeVay D, eds. Recent Progress in Neurologic Surgery. Amsterdam: Excerpta Medica; 1974:129-132.
35. Benedetti S, Dimeco F, Pollo B, et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum Gene Ther. 1997;8:1345-1353.